Organogenesis Holdings Inc. (ORGO): Price and Financial Metrics


Organogenesis Holdings Inc. (ORGO): $5.00

-0.23 (-4.40%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ORGO to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ORGO POWR Grades


  • ORGO scores best on the Value dimension, with a Value rank ahead of 97.65% of US stocks.
  • ORGO's strongest trending metric is Momentum; it's been moving down over the last 179 days.
  • ORGO ranks lowest in Momentum; there it ranks in the 16th percentile.

ORGO Stock Summary

  • With a year-over-year growth in debt of 56.07%, Organogenesis Holdings Inc's debt growth rate surpasses 84.76% of about US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, Organogenesis Holdings Inc is reporting a growth rate of 138.66%; that's higher than 85.42% of US stocks.
  • In terms of volatility of its share price, ORGO is more volatile than 85.68% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to Organogenesis Holdings Inc, a group of peers worth examining would be IOSP, MGIC, PERI, OFLX, and JOUT.
  • Visit ORGO's SEC page to see the company's official filings. To visit the company's web site, go to organogenesis.com.

ORGO Valuation Summary

  • In comparison to the median Healthcare stock, ORGO's price/sales ratio is 55.07% lower, now standing at 5.1.
  • ORGO's price/sales ratio has moved NA NA over the prior 57 months.
  • Over the past 57 months, ORGO's EV/EBIT ratio has gone NA NA.

Below are key valuation metrics over time for ORGO.

Stock Date P/S P/B P/E EV/EBIT
ORGO 2021-08-31 5.1 12.3 31.3 27.0
ORGO 2021-08-30 4.8 11.7 29.9 25.8
ORGO 2021-08-27 4.7 11.5 29.3 25.3
ORGO 2021-08-26 4.6 11.1 28.4 24.5
ORGO 2021-08-25 4.6 11.2 28.7 24.8
ORGO 2021-08-24 4.6 11.1 28.3 24.5

ORGO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ORGO has a Quality Grade of B, ranking ahead of 77.36% of graded US stocks.
  • ORGO's asset turnover comes in at 1.426 -- ranking 12th of 681 Pharmaceutical Products stocks.
  • VRTX, ACOR, and TPST are the stocks whose asset turnover ratios are most correlated with ORGO.

The table below shows ORGO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 1.426 0.760 0.406
2021-03-31 1.409 0.752 0.298
2020-12-31 1.401 0.742 0.166
2020-09-30 1.373 0.732 0.035
2020-06-30 1.315 0.709 -0.159
2020-03-31 1.377 0.707 -0.204

ORGO Price Target

For more insight on analysts targets of ORGO, see our ORGO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $26.75 Average Broker Recommendation 1.12 (Strong Buy)

ORGO Stock Price Chart Interactive Chart >

Price chart for ORGO

ORGO Price/Volume Stats

Current price $5.00 52-week high $17.50
Prev. close $5.23 52-week low $4.74
Day low $4.93 Volume 2,738,052
Day high $5.32 Avg. volume 1,071,234
50-day MA $5.98 Dividend yield N/A
200-day MA $8.86 Market Cap 645.65M

Organogenesis Holdings Inc. (ORGO) Company Bio


Organogenesis Holdings Inc. operates as a holding company. The Company, through its subsidiaries, focuses on development, manufacturing, and commercializing drugs and medicines for wound care, surgical, and sports medicine markets. Organogenesis Holdings serves customers in the United States and Switzerland.


ORGO Latest News Stream


Event/Time News Detail
Loading, please wait...

ORGO Latest Social Stream


Loading social stream, please wait...

View Full ORGO Social Stream

Latest ORGO News From Around the Web

Below are the latest news stories about Organogenesis Holdings Inc that investors may wish to consider to help them evaluate ORGO as an investment opportunity.

Organogenesis Appoints Michael J. Driscoll, Ed.D. to Board of Directors

CANTON, Mass., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced the appointment of Michael J. Driscoll, Ed.D. to the Company’s Board of Directors, effective February 15, 2022. Dr. Driscoll will serve as an independent director of the Company and member of the Aud

Yahoo | February 17, 2022

Organogenesis (ORGO) Stock Jumps 7.4%: Will It Continue to Soar?

Organogenesis (ORGO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Yahoo | February 16, 2022

Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in February

CANTON, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that company management will participate in the following upcoming investor conferences: The BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference Management will partici

Yahoo | February 11, 2022

Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2021 Financial Results on March 1, 2022

CANTON, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that fourth quarter and fiscal year 2021 financial results will be reported after the market closes on Tuesday, March 1st. Management will host a conference call at 5:00 p.m. Eastern Time on March 1s

Yahoo | February 7, 2022

Emerald Mutual Fund Advisers Trust Buys Customers Bancorp Inc, Herc Holdings Inc, ACADIA ...

Leola, PA, based Investment company Emerald Mutual Fund Advisers Trust (Current Portfolio) buys Customers Bancorp Inc, Herc Holdings Inc, ACADIA Pharmaceuticals Inc, Karuna Therapeutics Inc, HireRight Holdings Corp, sells Chegg Inc, BellRing Brands Inc, Echo Global Logistics Inc, Tetra Tech Inc, ORIC Pharmaceuticals Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Emerald Mutual Fund Advisers Trust.

Yahoo | February 2, 2022

Read More 'ORGO' Stories Here

ORGO Price Returns

1-mo -12.59%
3-mo -30.94%
6-mo N/A
1-year -70.45%
3-year -31.88%
5-year N/A
YTD -45.89%
2021 22.71%
2020 56.55%
2019 N/A
2018 0.00%
2017 N/A

Continue Researching ORGO

Want to see what other sources are saying about Organogenesis Holdings Inc's financials and stock price? Try the links below:

Organogenesis Holdings Inc (ORGO) Stock Price | Nasdaq
Organogenesis Holdings Inc (ORGO) Stock Quote, History and News - Yahoo Finance
Organogenesis Holdings Inc (ORGO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5316 seconds.